ArticleDiscover oncology2026
Probing uric acid-related prognostic genes and their molecular mechanisms in prostate cancer based on transcriptomic data.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies highlight the role of uric acid in tumor development, but its impact on prostate cancer (PCa) remains underexplored. This study aimed to investigate how uric acid influences PCa prognosis by analyzing transcriptomic data on PCa and uric acid-related genes (UARGs) from public databases. Differential expression analysis, protein-protein interaction (PPI) network, univariate Cox regression, and machine learning were used to identify prognostic genes. A risk model was then constructed based on these genes. Six prognostic genes (AHSG, AOX1, APOC1, LPL, NKX2-2, NKX6-1) were identified through the analysis of 1 433 differentially expressed genes (DEGs) and 3 806 UARGs. The risk model showed strong predictive ability, with the high-risk group (HRG) exhibiting poorer prognosis. Additionally, 10 immune cell types were significantly different between risk groups, with the HRG showing higher tumor mutation burden. A total of 8 drugs were found to correlate with risk scores. Enrichment analysis revealed that AHSG, AOX1, and APOC1 were linked to oxidative stress and Parkinson's disease, while NKX2-2 and NKX6-1 were associated with RNA degradation. These findings suggest that oxidative stress may be a key mechanism in PCa progression. This study offers a novel perspective on PCa treatment by identifying 6 prognostic genes and providing a prognostic risk model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.